Shares of Nurix Therapeutics Inc. (NRIX) soared more than 26% yesterday to touch a new 52-week high of $17.51, driven by news of the first clinical evidence of central nervous system activity of its drug candidate NX-5948.
NX-5948 is a brain-penetrant, orally available, BTK degrader, currently being evaluated in a Phase 1a/1b clinical trial in patients with relapsed or refractory B cell malignancies.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.